5 Components of a Patient-Centric eCOA Strategy for Oncology Clinical Trials

5 Components of a Patient-Centric eCOA Strategy for Oncology Clinical Trials

Melissa Mooney, Director of eCOA Solutions Engineering at IQVIAIn the US alone, an estimated 1.9 million new cases of cancer were diagnosed in 2022, positioning oncology as a key subject of clinical research. Throughout oncology trial development, it is important that stakeholders acknowledge that only patients can fully understand the impact of treatment on their lives. Regulators are now looking beyond clinical indications such as tumor size and delayed disease progression. When evaluating the risks and benefits of treatment, they want to know whether the side effects are tolerable for patients and how these treatments could be improved from the patient’s…

Continue Reading
Why Federally Mandated Electronic Prescribing for Controlled Substances will Benefit Public Health

Why Federally Mandated Electronic Prescribing for Controlled Substances will Benefit Public Health

Although 2022 has brought on a greater sense of normalcy, the past few years have distracted us from one of the most overlooked epidemics plaguing healthcare: prescription drug abuse.
Before Covid-19 diverted attention away from this problem, President Trump signed on to the SUPPORT for Patients and Communities Act of 2018, instating sweeping legislation for initiatives to address the opioid epidemic. The bill, among other initiatives, requires electronic prescriptions for controlled substances (EPCS) for any covered part D drug. Although the official start of the mandate was delayed two years to January 1, 2023, the importance of this federal intervention cannot be…

Continue Reading
Apellis Drug Becomes First Approved Therapy for Vision-Loss Disorder Geographic Atrophy

Apellis Drug Becomes First Approved Therapy for Vision-Loss Disorder Geographic Atrophy

Geographic atrophy, an eye disorder that starts as a loss of central vision and progressively worsens to total blindness, now has its first treatment. The FDA on Friday approved an Apellis Pharmaceuticals drug that slows the progression of this disease, which affects more than 1 million people in the U.S.
Approval of the Apellis drug, pegcetacoplan, covers all patients with geographic atrophy, a broad label that reflects the representative patient population tested in pivotal studies, Chief Medical Officer Caroline Baumal said during a Friday evening conference call. The Waltham, Massachusetts-based company plans to launch the drug in March, marketing the product under…

Continue Reading
Decline of Telehealth During the Pandemic and After

Decline of Telehealth During the Pandemic and After

The pandemic has forced healthcare organizations to rely heavily on telehealth services. In 2020, virtual visits accounted for more than a quarter of all outpatient visits in the U.S., and they’ve been steadily increasing since then. But there is a flip side to this trend. Recent data shows that telehealth is declining in healthcare, which could create a burden for both healthcare systems and patients. Let’s take a look at why this is happening and what can be done about it.
Reasons behind the decline  There are several factors driving the decline in telehealth utilization in healthcare settings. One reason is cost…

Continue Reading
Fatty Liver Disease in Children: Prevalence, Evaluation, & Essential Tools

Fatty Liver Disease in Children: Prevalence, Evaluation, & Essential Tools

Dr. Alisha Mavis, a Pediatric Hepatologist at Duke University where she cares for pediatric patients with liver disease joins eHealth Radio and the Children’s Health & Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Alisha Mavis discuss the following:
What is the prevalence of fatty liver disease in children, and who should we be screening?
When screening a child for fatty liver disease, what are some of the tools used to evaluate for the disease, and how is the diagnosis of pediatric fatty liver disease made?
What is the natural history of pediatric liver disease, and how does this…

Continue Reading
HIMSSCast: Epic leaders on data-driven clinical trial innovation

HIMSSCast: Epic leaders on data-driven clinical trial innovation

The challenges of designing effective clinical trials, finding the right people to participate in them and building trial cohorts that are representative of the population at large, have been well-documented.With its recent Life Sciences initiative, Epic has set its sights on data-driven insights to improve the development of new therapeutics and interventions. That includes improving all parts of the clinical trial process – from how physicians educate their patients about potential cohorts, matching and connecting patients with promising research and helping make sure those studies are optimally beneficial for as many people as possible. Epic is already helping its provider customers…

Continue Reading
Personalized CAR-T Cell Therapy

Personalized CAR-T Cell Therapy

Researchers at the Harvard Wyss Institute and the Dana-Farber Cancer Institute have developed a new method to prepare chimeric antigen receptor-T cells (CAR-T cells) for leukemia patients that could result in more effective treatment. CAR-T cells start life as T cells that are isolated from cancer patients, are stimulated and primed to recognize and attack cancer cells, expanded in number, and then reintroduced to the cancer patient with the goal that the cells will destroy their cancer. However, the technique works better in certain patients, and the researchers behind this latest technique have realized that T-cells from cancer patients do […]…

Continue Reading
What the metaverse and virtual reality can contribute to healthcare

What the metaverse and virtual reality can contribute to healthcare

The so-called metaverse and virtual reality are up-and-coming technologies that could offer healthcare quite a bit.Medical practitioners can test out the effectiveness of new surgical methods in the metaverse before attempting on real patients. And as an extension of telehealth, medical professionals can use virtual reality to access patients and examine them virtually.
What exactly is the metaverse? How does virtual reality work? What can they contribute to healthcare? And where will these technologies offer innovations in the years to come?
To get answers to these questions, we sat down with Pari Natarajan, CEO of Zinnov, a global management and consulting firm focusing…

Continue Reading
Q&A: How the PHE's end could affect telehealth, patient care

Q&A: How the PHE’s end could affect telehealth, patient care

The public health emergency declared in early 2020 was put in place to provide waivers from the Centers for Medicare and Medicaid Services to ease the burden on hospitals and other providers during the pandemic. It has been extended 12 times since its implementation and is finally slated to end on May 11. Heather Meade, principal at Washington Council Ernst & Young, spoke with MobiHealthNews about how the end of the PHE could affect telemedicine companies’ funding streams and patients’ access to care.  
MobiHealthNews: What are the benefits and detriments to the PHE ending, especially for telehealth?
Meade: I mean, we need permanent policy…

Continue Reading
DrFirst Acquires Diagnotes Secure Messaging and Care Coordination Platform

DrFirst Acquires Diagnotes Secure Messaging and Care Coordination Platform

Expands Backline by DrFirst’s Capabilities for Clinical Communications in Health Systems and Beyond
Healthcare technology pioneer DrFirst today announced it has acquired select assets of Indianapolis-based Diagnotes. The acquisition will allow Backline by DrFirst to expand its capabilities to break through communication silos in healthcare at each stage of the patient care journey, promote positive patient outcomes, and enhance satisfaction for staff and patients.
Diagnotes provides a suite of team-based, patient-centered collaboration tools built specifically for the healthcare sector. The app increases clinicians’ productivity and the quality of patient care by allowing healthcare providers to communicate with colleagues in their system and affiliates in other systems. The…

Continue Reading